JPWO2023282296A1 - - Google Patents
Info
- Publication number
- JPWO2023282296A1 JPWO2023282296A1 JP2023533170A JP2023533170A JPWO2023282296A1 JP WO2023282296 A1 JPWO2023282296 A1 JP WO2023282296A1 JP 2023533170 A JP2023533170 A JP 2023533170A JP 2023533170 A JP2023533170 A JP 2023533170A JP WO2023282296 A1 JPWO2023282296 A1 JP WO2023282296A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11021—Polo kinase (2.7.11.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021113189 | 2021-07-07 | ||
| PCT/JP2022/026863 WO2023282296A1 (ja) | 2021-07-07 | 2022-07-06 | ｐＨ応答性脂質誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2023282296A1 true JPWO2023282296A1 (https=) | 2023-01-12 |
Family
ID=84801663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533170A Pending JPWO2023282296A1 (https=) | 2021-07-07 | 2022-07-06 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240374733A1 (https=) |
| EP (1) | EP4368657A4 (https=) |
| JP (1) | JPWO2023282296A1 (https=) |
| WO (1) | WO2023282296A1 (https=) |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001508815A (ja) * | 1996-05-29 | 2001-07-03 | セル ジェネシス，インコーポレイテッド | カチオン性ポリマー／脂質核酸送達ビヒクル |
| JP2001515051A (ja) * | 1997-08-13 | 2001-09-18 | カイロン コーポレイション | 核酸送達用の脂質−ポリアミド結合体および組成物 |
| JP2004527586A (ja) * | 2001-06-01 | 2004-09-09 | ヤマノウチ ユーロープ ベスローテン フェンノートシャップ | 脂質−ポリマー結合体組成物 |
| JP2007505954A (ja) * | 2003-09-15 | 2007-03-15 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| JP2008516056A (ja) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | リポポリマーコンジュゲート |
| JP2008214516A (ja) * | 2007-03-05 | 2008-09-18 | Terumo Corp | ポリサルコシン誘導体及びこれを膜構成成分とする薬物担体 |
| JP2012087142A (ja) * | 2003-12-19 | 2012-05-10 | Novartis Vaccines & Diagnostics Inc | 短鎖干渉ｒｎａの細胞トランスフェクティング処方物、関連する組成物および作製方法ならびに使用 |
| WO2013162041A1 (ja) * | 2012-04-27 | 2013-10-31 | 国立大学法人 東京大学 | 核酸デリバリー用ユニット構造型医薬組成物 |
| WO2016199895A1 (ja) * | 2015-06-10 | 2016-12-15 | 学校法人慶應義塾 | 核酸送達用キャリア、核酸送達用キット、及び核酸送達方法 |
| WO2018110366A1 (ja) * | 2016-12-15 | 2018-06-21 | 国立大学法人東京工業大学 | ｐＨ応答性ポリマー及び薬物送達システム |
| WO2019004482A1 (ja) * | 2017-06-26 | 2019-01-03 | 国立大学法人東京大学 | 複素環式ボロン酸誘導体 |
| WO2019189867A1 (ja) * | 2018-03-30 | 2019-10-03 | 三井化学株式会社 | ビスイミノビオチン化合物の薬物送達用の用途 |
| WO2019210326A2 (en) * | 2018-04-27 | 2019-10-31 | Genedit Inc. | Cationic polymer and use for biomolecule delivery |
| WO2020006340A1 (en) * | 2018-06-28 | 2020-01-02 | University Of Massachusetts | Compositions and methods for protein labeling, modification, analysis, and targeted delivery |
| US20210181185A1 (en) * | 2017-11-09 | 2021-06-17 | Mindimmune Therapeutics, Inc. | Dendritic cell recruitment from blood to brain in neurodegenerative disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046278A1 (en) * | 2017-08-28 | 2019-03-07 | Wake Forest University | CONCEPTS OF USEFUL LOADS AND BINDING SEGMENTS FOR ANTICANCER AGENTS AND ASSOCIATED METHODS |
| KR102906643B1 (ko) | 2020-01-20 | 2025-12-31 | 삼성디스플레이 주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 상기 유기 발광 소자를 포함한 전자 장치 |
-
2022
- 2022-07-06 JP JP2023533170A patent/JPWO2023282296A1/ja active Pending
- 2022-07-06 US US18/577,158 patent/US20240374733A1/en active Pending
- 2022-07-06 EP EP22837710.7A patent/EP4368657A4/en active Pending
- 2022-07-06 WO PCT/JP2022/026863 patent/WO2023282296A1/ja not_active Ceased
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001508815A (ja) * | 1996-05-29 | 2001-07-03 | セル ジェネシス，インコーポレイテッド | カチオン性ポリマー／脂質核酸送達ビヒクル |
| JP2001515051A (ja) * | 1997-08-13 | 2001-09-18 | カイロン コーポレイション | 核酸送達用の脂質−ポリアミド結合体および組成物 |
| JP2007161722A (ja) * | 1997-08-13 | 2007-06-28 | Chiron Corp | 核酸送達用の脂質−ポリアミド結合体および組成物 |
| JP2004527586A (ja) * | 2001-06-01 | 2004-09-09 | ヤマノウチ ユーロープ ベスローテン フェンノートシャップ | 脂質−ポリマー結合体組成物 |
| JP2007505954A (ja) * | 2003-09-15 | 2007-03-15 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| JP2012087142A (ja) * | 2003-12-19 | 2012-05-10 | Novartis Vaccines & Diagnostics Inc | 短鎖干渉ｒｎａの細胞トランスフェクティング処方物、関連する組成物および作製方法ならびに使用 |
| JP2008516056A (ja) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | リポポリマーコンジュゲート |
| JP2008214516A (ja) * | 2007-03-05 | 2008-09-18 | Terumo Corp | ポリサルコシン誘導体及びこれを膜構成成分とする薬物担体 |
| WO2013162041A1 (ja) * | 2012-04-27 | 2013-10-31 | 国立大学法人 東京大学 | 核酸デリバリー用ユニット構造型医薬組成物 |
| WO2016199895A1 (ja) * | 2015-06-10 | 2016-12-15 | 学校法人慶應義塾 | 核酸送達用キャリア、核酸送達用キット、及び核酸送達方法 |
| WO2018110366A1 (ja) * | 2016-12-15 | 2018-06-21 | 国立大学法人東京工業大学 | ｐＨ応答性ポリマー及び薬物送達システム |
| WO2019004482A1 (ja) * | 2017-06-26 | 2019-01-03 | 国立大学法人東京大学 | 複素環式ボロン酸誘導体 |
| US20210181185A1 (en) * | 2017-11-09 | 2021-06-17 | Mindimmune Therapeutics, Inc. | Dendritic cell recruitment from blood to brain in neurodegenerative disease |
| WO2019189867A1 (ja) * | 2018-03-30 | 2019-10-03 | 三井化学株式会社 | ビスイミノビオチン化合物の薬物送達用の用途 |
| WO2019210326A2 (en) * | 2018-04-27 | 2019-10-31 | Genedit Inc. | Cationic polymer and use for biomolecule delivery |
| WO2020006340A1 (en) * | 2018-06-28 | 2020-01-02 | University Of Massachusetts | Compositions and methods for protein labeling, modification, analysis, and targeted delivery |
Non-Patent Citations (2)
| Title |
|---|
| LEGENDRE Y. J. ET AL.: "Dioleoylmelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells", BIOCONJUGATE CHEM., vol. 8, JPN6022040011, 1997, US, pages 57 - 63, ISSN: 0005839044 * |
| RANNEH,ABDUL-HACKAM: "An Ethylenediamine-based Switch to Render the Polyzwitterion Cationic at Tumorous pH for Effective T", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 57, JPN6022040012, 2018, pages 5057 - 5061, ISSN: 0005839045 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240374733A1 (en) | 2024-11-14 |
| WO2023282296A1 (ja) | 2023-01-12 |
| EP4368657A1 (en) | 2024-05-15 |
| EP4368657A4 (en) | 2025-07-02 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20240115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260414 |